Mon, 17 Mar 2003 14:58:30 -0600 http://www.sidp.org/ SIDP en-us http://www.sidp.org/images/accp_logo.gif http://www.sidp.org/ admin@sidp.org http://www.sidp.org/Article3.html Clinical Applications of Direct Clinical Applications of Direct Thrombin Inhibitors   Tom Vondracek,Pharm.D., BCPS   Objectives By the conclusion of this presentation the pharmacist shall be able to:   1.     Compare and contrast the pharmacologic profiles of the different direct thrombin inhibitors.   2.     Discuss the different clinical situations in which these agents may be used.   3.     Describe the proper monitoring parameters when using these agents.     Pre/Post Questions   1.        Which of the following agents is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty?   Argatroban Lepirudin Bivalirudin All the above   2.     Which of the following agents do not require dose adjustment for renal dysfunction?   Argatroban Lepirudin Bivalirudin All the above   3.        In a patient receiving a direct thrombin inhibitor for the treatment of heparin-induced thrombocytopenia, which of the following are recommended monitoring parameters?   A     aPTT Platelet count C.       H/H Signs and symptoms of bleeding or thrombosis All the above should be monitored   4.        Which of the following are clinical scenarios in which direct thrombin inhibitors may be utilized?   Treatment of Heparin-induced thrombocytopenia (HIT) As a replacement for heparin in a patient receiving a coronary stent As a replacement for heparin in a patient undergoing hemodialysis Prevention of the development of HIT All of the above   5.     Which of the following agents is recommended to be dosed as a continuous infusion, with no need for a loading dose?   Argatroban Lepirudin Bivalirudin All the above Mon, 17 Mar 2003 14:58:30 -0600 http://www.sidp.org/Article2.html test2 Sat, 15 Mar 2003 15:50:11 -0600 http://www.sidp.org/Article1.html This is a sample article about the MACCP site launching. Mon, 20 Jan 2003 18:47:36 -0600